CagriSema

CagriSema is Novo Nordisk's weekly subcutaneous shot pairing semaglutide (the GLP-1 receptor agonist behind Ozempic and Wegovy) with cagrilintide, a first-in-class long-acting amylin analog. Novo is testing it across a Phase 3 program that spans obesity (REDEFINE 1), T2D plus obesity (REDEFINE 2), cardiovascular outcomes (REDEFINE 3), three T2D registrational studies (REIMAGINE 1, 2, 3), and a head-to-head against Eli Lilly's tirzepatide. Novo filed the U.S. NDA for chronic weight management in Q1 2026 based on the REDEFINE package [11]. The bet: hitting two satiety pathways at once beats GLP-1 monotherapy and reclaims share Lilly's tirzepatide has been taking. Data so far are mixed. REDEFINE 1 in obesity hit its primary endpoint but delivered 22.7% mean weight loss, below Novo's telegraphed 25% target, which cost the stock roughly 20% in one session on December 20, 2024 and wiped out about €90B in market capitalization [4][8]. The head-to-head Phase 3 against tirzepatide in T2D (NCT06534411, n=1,023) completed enrollment and topline is the next major event on the calendar, expected in Q4 2026 [6]. That readout decides whether CagriSema anchors a $10B franchise or a $30B one. Novo Nordisk reported approximately $42B in 2024 revenue (DKK 290.4B) built almost entirely on GLP-1 economics, so this program is the primary defense against Lilly [10].

CagriSema is a fixed-ratio combination of two peptides. Semaglutide is already approved as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral T2D). Cagrilintide is a novel entity, never approved anywhere. That makes CagriSema a combo product built on a validated backbone plus a first-in-class partner, not a repurposed drug and not a fully new compound. The Phase 3 program is unusually broad. REDEFINE 1 (NCT05567796, n=3,400) in obesity read out December 2024 [4][8]. REDEFINE 2 (n=1,206) tested CagriSema in adults with both T2D and overweight or obesity over 68 weeks and hit its endpoints [11]. REDEFINE 3 (NCT05669755, n=7,101) is a cardiovascular outcomes trial testing 3-point MACE [5]. REIMAGINE 1 and REIMAGINE 2 were published in Lancet Diabetes and Endocrinology in 2026 and REIMAGINE 3 (basal-insulin add-on) was published in The Lancet in 2026 [1][2][12]. The head-to-head Phase 3 versus tirzepatide in T2D (NCT06534411, n=1,023) has completed enrollment [6], and topline is expected in Q4 2026. A dose-optimization Phase 3 in obesity is also recruiting per Novo's pipeline disclosures, though the specific NCT identifier previously cited (NCT07564414) could not be verified on ClinicalTrials.gov and has been dropped from this writeup pending confirmation. Novo filed the U.S. NDA for chronic weight management in Q1 2026 [11]. No FDA breakthrough or fast track designation is public. Timing on the CV outcomes trial extends into 2027 or later depending on event accrual.

Two hormones, two brakes on appetite. Semaglutide mimics GLP-1, a gut hormone released after eating that tells the pancreas to release insulin and tells the brain you are full. It also slows how fast food leaves the stomach. That is why Ozempic and Wegovy work: cut hunger and slow digestion, patients eat less. Amylin is the other satiety hormone. It is co-secreted from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon (which normally raises blood sugar), and hits appetite centers in the hindbrain through a different receptor than GLP-1. That receptor is a complex of the calcitonin receptor plus a helper protein called RAMP. Cagrilintide binds that complex and sticks around for a week, matching semaglutide's dosing rhythm. The two-hormone bet is biologically defensible. In animal models, amylin plus GLP-1 produces more weight loss than either alone. Phase 2 CagriSema data (from the COMBINE program) showed additive benefit versus semaglutide monotherapy at 32 weeks. The Phase 3 question was whether that additive signal survives at scale and whether the combined signal beats tirzepatide, Lilly's dual GLP-1/GIP agonist that has set the weight-loss ceiling. Amylin has commercial precedent. Symlin (pramlintide) has been approved since 2005 but its short half-life and mealtime dosing limited uptake. Cagrilintide's weekly profile finally makes the amylin arm practical. If the combination shows a meaningful advantage over semaglutide monotherapy, cagrilintide validates a mechanism that has been commercially frozen for two decades.

The Phase 3 program is broad by design. REDEFINE 1 (NCT05567796) enrolled 3,400 adults with obesity, with percent change in body weight at 68 weeks versus placebo as the primary endpoint. It hit statistically but with 22.7% mean weight loss versus Novo's telegraphed 25% target [4][8]. The gap moved the stock more than the topline p-value. REDEFINE 2 (n=1,206) enrolled adults with T2D and overweight or obesity for 68 weeks. CagriSema delivered 15.7% weight loss (per-protocol) versus 3.1% for placebo, or 13.7% versus 3.4% under treatment-policy analysis, with 89.7% of patients hitting the 5% weight loss threshold versus 30.3% on placebo [11]. REDEFINE 3 (NCT05669755) is the cardiovascular outcomes trial: 7,101 patients with atherosclerotic disease, 3-point MACE (major adverse cardiovascular events, defined as cardiovascular death, myocardial infarction/heart attack, and stroke) as the primary endpoint, active but not recruiting [5]. Readout timing depends on event accrual, likely 2027 or 2028. REIMAGINE 1, 2, and 3 are the T2D registrational studies. HbA1c (a blood marker reflecting average blood sugar over roughly the prior three months) is the primary endpoint across the set. REIMAGINE 1 (n=189, 40 weeks) tested CagriSema against placebo in patients uncontrolled on diet and exercise: the 2.4/2.4 mg dose reduced HbA1c by 1.8% and body weight by 13.8%, with 90% of patients hitting the 5% weight loss threshold [1][13]. REIMAGINE 2 (n=2,713, 68 weeks) compared CagriSema against semaglutide 2.4 mg, cagrilintide 2.4 mg, and placebo in patients on metformin with or without an SGLT2 inhibitor, a design that isolates the combination effect: CagriSema 2.4/2.4 mg reduced HbA1c by 1.91% and weight by 14.2%, superior to both semaglutide monotherapy and cagrilintide monotherapy on both endpoints [2][13]. REIMAGINE 3 tested CagriSema as an add-on to basal insulin and also met its primary endpoint [12]. NCT06534411 is the direct comparison against Lilly's tirzepatide in metformin- or SGLT2-treated T2D patients, n=1,023, primary endpoint change in HbA1c. Enrollment complete [6]. Topline (expected Q4 2026) is the single most important upcoming data point for the CagriSema thesis. The head-to-head is unusual for a large pharma to run against a competitor. Novo needed it because Lilly's tirzepatide had already outperformed semaglutide in SURPASS-2. Beating tirzepatide, or matching it, is the only way CagriSema pricing power stays intact against Zepbound and Mounjaro.

Our model estimates a 35% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 66%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual and the sponsor's strong record of getting drugs approved; it is held back by heavier-than-usual blinding and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy: REDEFINE 1's 22.7% weight loss beat placebo cleanly but fell short of expectations [4][8]. Tirzepatide delivered roughly 22.5% mean weight loss in SURMOUNT-1 as monotherapy at the top dose, meaning CagriSema's expected combination advantage did not show up in cross-trial comparison [9]. That is a real problem for a drug designed to leapfrog tirzepatide. REIMAGINE 2 offered partial recovery (14.2% weight loss superior to semaglutide monotherapy in T2D) [2], but the pending head-to-head (NCT06534411) will settle whether the two are equivalent in T2D, whether one wins on HbA1c, and whether tolerability profiles differ [6]. Safety: GI adverse events (nausea, vomiting, diarrhea) drive dropout in every incretin trial. In Phase 2, CagriSema had higher dropout than semaglutide alone. Amylin stacks nausea on top of GLP-1 nausea. Dropout matters statistically because when patients leave the trial early, their missing weight data has to be estimated. Different estimation methods (per-protocol vs. intent-to-treat, or 'treatment policy') can produce meaningfully different headline numbers, and the FDA and payers evaluate both. REDEFINE 2 showed roughly a 2-point spread between per-protocol (15.7%) and treatment-policy (13.7%) weight loss estimates, which is a live example of this dynamic [11]. Execution: a dose-optimization Phase 3 in obesity is still recruiting, suggesting Novo is tuning the ratio and titration late. Late-stage dose refinement is workable but expensive, and it signals the initial Phase 3 dose was not optimal. The specific NCT ID for this study previously cited in this writeup (NCT07564414) could not be verified against ClinicalTrials.gov and has been dropped pending confirmation from Novo's pipeline disclosures. Commercial: even with approval and even if efficacy matches tirzepatide, Novo faces margin and pricing pressure specific to a dual-peptide product. Manufacturing two long-acting peptides in one weekly injection is inherently higher-cost than Lilly's single-molecule tirzepatide, which structurally caps CagriSema's ability to compete on price. On the long horizon, semaglutide's U.S. composition-of-matter patent expires in 2032 with formulation and method-of-use patents pushing biosimilar entry to roughly 2033-2035, so Novo needs CagriSema to establish premium positioning before its GLP-1 backbone faces biosimilar erosion [14]. Wegovy and Zepbound have been supply-constrained and heavily discounted through PBM contracts. Compounded semaglutide, oral GLP-1 pills, and Lilly's next-generation candidates (retatrutide, orforglipron) land on overlapping timelines. Payers will demand cardiovascular outcomes evidence, which is why REDEFINE 3 matters as much as the weight-loss numbers [5]. Regulatory: combination product classification could complicate label negotiations, but the components' individual safety files are well-established.

Worth watching. This is the biggest metabolic readout on the near-term calendar and a direct referendum on whether combination biology can catch tirzepatide. The single data point that matters: NCT06534411 topline (expected Q4 2026), CagriSema versus tirzepatide in T2D [6]. Enrollment completed. HbA1c is the primary endpoint, but the weight-loss secondary is what moves the story. If CagriSema wins or draws on both, Novo re-anchors the obesity narrative and pricing power. If it loses on either, tirzepatide's structural lead solidifies and Novo's pipeline pressure shifts to amycretin (Novo's own unimolecular oral peptide that combines GLP-1 and amylin activity in a single molecule, currently in Phase 2) and the next-generation candidates. Second data point: REDEFINE 3 interim cardiovascular outcomes accrual [5]. CV outcomes are the label expansion payers demand and Novo's parallel to SELECT (semaglutide CV data). Commercial context. Novo Nordisk reported approximately $42B in 2024 revenue (DKK 290.4B) with GLP-1 franchises carrying the P&L [10]. CagriSema is the primary growth vector to defend that revenue against Lilly's tirzepatide franchise. The U.S. NDA for chronic weight management was filed Q1 2026 based on the REDEFINE package [11]. The market already priced in some CagriSema disappointment after the December 20, 2024 selloff of roughly 20% that wiped ~€90B in market capitalization. The head-to-head resets expectations either way. Long-horizon overhang. Semaglutide's U.S. patent cliff (composition of matter 2032, biosimilar entry realistically 2033-2035) [14] and the higher manufacturing cost of a dual-peptide weekly injection vs. tirzepatide's single molecule together mean CagriSema needs to establish premium clinical positioning early. The tirzepatide head-to-head is where that positioning is won or lost. Check back after the NCT06534411 topline lands. That result determines whether Novo remains a growth story or shifts to a defensive posture in metabolic disease.